Palatin Technologies Unveils Promising MC4R Agonist Data at ObesityWeek 2025 Palatin Technologies presents significant findings on its MC4R agonist, PL7737, showcasing its potential for safe and effective obesity treatment at ObesityWeek 2025.

Palatin Technologies Unveils Promising MC4R Agonist Data at ObesityWeek 2025 #USA #Atlanta #Palatin_Technologies #MC4R_agonist #PL7737

Palatin Technologies Presents Strong Preclinical Results of PL7737 for Obesity Treatment Palatin Technologies has revealed promising preclinical efficacy data for its oral MC4R agonist, PL7737, highlighting significant weight loss in animal models of obesity.

Palatin Technologies Presents Strong Preclinical Results of PL7737 for Obesity Treatment #USA #Palatin_Technologies #Princeton #MC4R_agonist #PL7737